AUTHOR INDEX TO VOLUME 46

Alonso C, 267
Beattie JH, 153
Bernier JL, 7
Bhattacharya PK, 223
Bontchev PR, 23
Bowman TD, 243
Buglyo P, 49
Casas JS, 17
Casella L, 161
Catteau JP, 7
Chen X, 231
Chiessi E, 109
Chohan ZH, 41
Cotelle N, 7
Couce MD, 17
Dhindsa KS, 119
Dias BA, 99
Djemil S, 49
Dudeja M, 119
Erre LS, 49
Evans GW, 243
Evtimova B, 23
Fatemi SJA, 35
Feng Q-P, 251
Ganther H, 215
Geraldes CFGC, 99
Gochev G, 23
Hénichart JP, 7
Horrocks WD Jr, 175, 193
Hu Y, 231
Ip C, 215
Isab AA, 145
Kadum H, 23
Kang B, 231
Kiss T, 49
Klakamp SL, 175, 193
Kostić NM, 77
Kozlowski H, 49
Li Y-L, 251
López-Rivadulla M, 17
López-Solera I, 267
Lu J, 231
Lukes AJ, 77
Malhotra R, 119
Mangani S, 1
Manohar H, 259
Martínez-Carrera S, 267
Masaguer JR, 267
Mathews II, 259
Messori L, 1
Micera G, 49
Moore GR, 35
Nachev C, 23
Navarro-Ranninger C, 267
Paradossi G, 109
Pérez JM, 267
Pezeshk A, 67
Pezeshk V, 67
Pintar A, 161
Pispisa B, 109
Rao MJ, 207
Rauf A, 41
Rhodes MD, 129
Rowatt E, 87
Sánchez A, 17
Sabbioni E, 161
Sadler PJ, 129
Saraiva ME, 99
Scawen MD, 129
Serra MA, 161
Silver S, 129
Singh JP, 119
Sordo J, 17
Subczynski WK, 67
Trémoliéres E, 7
Varela JM, 17
Varghese A, 223
Venanzi M, 109
Wang S-X, 251
Weersink E, 153
Weng L, 231
Williams RJP, 87
Williamson DJ, 35
Wojas J, 67
Wu D, 231
Xu Y, 231
Zamora F, 267
Zhang F-J, 251

SUBJECT INDEX TO VOLUME 46

Acid hydrazides
  biocidal agents, 119
  fungi and, 119
  n-substituted, 119
Adriamycin, antitumor activity of, 67
Albumin, aluminum binding to transferrin and, 35
Alcohols, arsenate and, 99
Aluminum
  albumin and transferrin and binding of, 35
  Alzheimer's disease and, 35
Alzheimer's disease, aluminum and, 35
Amino acids
  cyclization of histidine Schiff base and, 259
  zinc(II) and cadmium(II) complexes and, 223
Angiotensin converting enzyme inhibitor, captopril, 23
Antibiotics
  adriamycin, 67
  daunomycin, 67
  D-cycloserine, *D*-4-amino-3-isoxazolidone, 49
Anticancer agents
  adriamycin, 67
  arsenite, 215
  daunomycin, 67
  trimethylselenonium, 215
Antitumor activity of palladium(II)-spermidine complexes, 267
Antioxidant enzymes, vanadium and, 161
Arsenate
  alcohols and, 99
  arsenic-75 nuclear magnetic resonance and, 99
  cationic centers and, 99
  monosaccharides and, 99
  pH and, 99
  polyols and, 99
Arsenic-75 nuclear magnetic resonance, 99
Arsenite
  selenium matabolism and, 215
  trimethylselenonium and, 215
Arthritis
  gold(I) and, 129, 145
  pseudomonas putida and antiarthritic drugs, 129
  thioglucose-gold(I)-$^{13}CN^-$ and, 145
Aurothioglucose, $^{13}CN^-$ and, 145
β-aminoxy-*D*-alanine, copper(II) complexes of *D*-cycloserine and, 49
Bacteria, gold(I) phosphines and, 129
Binary and mixed ligand complexes, N,2'-diphenyl acetohydroxamic acid, 207
Biocidal agents, acid hydrazides and, 119
Borate and molybdate inhibition, catechol estrogen and pyrocatechol methylation, 153
Boron and molybdenum anions, sex steroid metabolism and, 153
Breast carcinoma, palladium(II)-spermidine complexes and, 267
Cadmium
  liver and, 17
  tetrahedral zinc(II) and, 223
  vitamin B_6 pyridoxine and, 17
Captopril, copper(II) and, 23
Carcinoma, palladium(II)-spermidine complexes and breast, 267
Catalase, vanadium effect on, 161
Catechol estrogens, borate and molybdate inhibition of, 153
Catechol-O-methyltransferase, borate and molybdate inhibition of sex steroid hormones by, 153
Cationic centers, arsentate and potential, 99
Chitosan, copper complexes immobilized to, 109
Chloromercuryferrocene, cytochrome *c* and, 77
Chromium, insulin internalization and, 243
Chromium chloride, insulin internalization and chromium picolinate vs., 243
Chromium nicotinate, insulin internalization and chromium picolinate vs., 243
Chromium picolinate, insulin internalization and, 243
Cis-diamminedichloroplatinum(II), antitumor activity of, 267
Cobalt(II), nickel(II), dithiooxamide ligands, and, 41
Copper complexes
  captopril and, 23
  chitosan and, 109
  D-cycloserine and β-aminoxy-*D*-alanine and, 49
  polymeric ligands and, 109
Crystallographic studies
  palladium(II)-spermidine compounds and, 267
  triply bridged complexes containing ligands and, 231
  Cytochrome *c*, chloromercuryferrocene and, 77
D-cycloserine, copper(II) complexes of β-aminoxy-*D*-alanine and, 49
Daunomycin
  antitumor activity of, 67
  lipid bilayers and spin-labeled, 67
  partitional and motional properties of, 67
Dithiooxamide ligands, cobalt(II) and nickel(II) with, 41
DNA binding, polyamines and magnesium in, 87
DNA structure, lanthanide ion probe of, 175, 195
Electron paramagnetic resonance studies
  copper(II) interaction with captopril, 23

copper complexes immobilized to chitosan and, 109
Electron spin resonance studies
daunomycin and, 67
nickel(II) oligopeptides and reduced oxygen species, 7
Electronic spectroscopic studies
hydroxyflavones and metals in, 251
vitamin B_6 and, 259
Eu^{3+} luminescence spectroscopy
guanine-containing oligomers and nucleotides in, 175
non-guanine-containing oligomers and nucleotides in, 193
EXAFS studies
molybdenum and, 231
oxlate derivative of iron transferrin, 1
5-hydroxy-7,4'-dimethoxyflavone, biological properties of transition metal complexes with, 251
Fungi, acid hydrazides and, 119
Fungicidal activity, N,2'-diphenyl acetohydroxamic acid and, 207
Glucose intolerance, chromium deficiency and, 243
Glutathione peroxidase, vanadium effect on, 161
Gold(I)
arthritis and, 129, 145
phosphines vs. thiolates, 129
pseudomonas putida and, 129
Gold(I) phosphines, bacteria and, 129
Guanine-containing oligomers and nucleotides, lanthanide ion luminescence and, 175
Histidines
cyclization of Schiff base, 259
zinc(II) and cadmium(II) complexes and, 223
Hormones, insulin and chromium, 243
Horseradish peroxidase, vanadium effect on, 161
Hydroxamic acids, metal ions and ligation of, 207
Hydroxyflavones, transition metal complexes and, 251
Hypertension, captopril and arterial, 23
Infrared spectroscopy studies
cobalt(II) and nickel(II) with dithiooxamide ligands in, 41
palladium(II)-spermidine complexes and, 267
Insulin internalization, chromium picolinate and, 243
Iron transferrin, oxalate derviative of, 1
Lanthanide ion probe, DNA structure and, 175, 193
Ligands
hydroxyflavone and metals, 251
N,2'-diphenyl acetohydroxamic acid and binary and mixed, 207
triply bridged complexes containing, 231
zinc(II) and cadmium(II) complexes with, 223
Liver, cadmium and, 17
Magnesium, DNA binding of polyamines and, 87
Mercury , toxicity of, 77
Metal complexes, 5-hydroxy-7,4'-dimethoxyflavone and transition, 251
Metal ions
cyclization reaction with pH and, 259
hydroxamic acid ligation to transition, 207
n-substituted acid hydrazides and, 119
vitamin B_6 and absence of, 259
Metalloenzymes, zinc(II) and cadmium(II) complexes and, 223
Molybdenum
sex steroid metabolism and, 153
sulfur-containing ligands and, 231
Monosaccharides, arsenate and, 99
N,2'-diphenyl acetohydroxamic acid, antifungal potential of binary and mixed-ligand complexes of, 207
N-substituted acid hydrazides, metals and, 119
Nickel(II)
dithiooxamide ligands with cobalt(II) and, 41
oligopeptides and reduced oxygen species, 7
Non-guanine-containing oligomers and nucleotides, lanthanide ion luminescence and, 193
Nuclear magnetic resonance spectroscopy
aluminum binding to albumin and transferrin, 35
arsenic-75, 99
cadmium, vitamin B_6, and, 17
cobalt(II) and nickel(II) with dithiooxamide ligands in, 41
palladium(II)-spermidine complexes and, 267
thioglucose-gold(I)-$^{13}CN^-$ complex and, 145
o-mercaptophenol ligands, triply bridged complexes containing, 231
Organomercurial, diproportionation with sulfhydryl-containing protein and, 77
Oxalate, iron transferrin and, 1
Oxomolybdenum(V) complexes, *o*-mercaptophenol ligands and triply bridged (O,O',S)-binuclear, 231
Oxygen species, nickel(II) oligopeptides and reduced, 7
Palladium(II)-spermidine complexes, antitumor activity and, 267
Peptides, nickel(II) oligopeptides and reduced oxygen species, 7
pH, arsenate and, 99
Polyamines, DNA binding of magnesium and, 87
Polymeric ligands, copper complexes and, 109
Polyols, arsenate and, 99
Polysaccharides-metal complexes, 109
Protein, disproportionation with organomercurial and sulfhydryl-containing, 77
Pseudomonas putida, gold(I) antiarthritic drugs and, 129
Pyridoxal-histamine cyclized Schiff base, pH and metal ions on decyclization reactions of, 259
Pyridoxine, cadium and vitamin B_6, 17
Pyrocatechol methylation, borate and molybdate inhibition of, 153

Selenium metabolism, arsenite and, 215
Sex steroid metabolism
  boron and molybdenum anions and, 153
  catechol-O-methyltransferase and, 153
Spermidine trihydrochloride, palladium(II) and, 267
Spermine, DNA binding of, 87
Sulfite oxidase, molybdenum complexes and, 231
Sulfur-containing ligands, molybdenum complexes and, 231
Superoxide dismutase, vanadium effect on, 161
Thioglucose-gold(I)-$^{13}CN^-$ complex
  arthritis and, 145
  nuclear magnetic resonance (NMR) spectroscopy and, 145
$^{13}CN^-$, aurothioglucose and, 145
Transferrins
  aluminum binding to albumin and, 35
  oxalate derivative of iron, 1
Trimethylselenonium
  arsenite and biological activities of, 215
  nutritional availability of, 215
  toxicity of, 215
Vanadium effect, antioxidant enzymes and, 161
Vitamin B_6
  non-enzymatic reactions with, 259
  pyridoxine and cadmium and, 17
Xanthine oxidase, molybdenum and, 231
Zinc(II) and cadmium(II) complexes, tetrahedral, 223